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Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable
risk. Here we perform a meta-analysis of three genome-wide association studies, with
replication in a fourth study, incorporating a total of 4018 AML cases and 10488 controls. We
identify a genome-wide significant risk locus for AML at 11q13.2 (rs4930561; P= 2.15 × 10−8;
KMT5B). We also identify a genome-wide significant risk locus for the cytogenetically normal
AML sub-group (N= 1287) at 6p21.32 (rs3916765; P= 1.51 × 10−10; HLA). Our results inform
on AML etiology and identify putative functional genes operating in histone methylation
(KMT5B) and immune function (HLA).
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Acute myeloid leukemia (AML) is the most common acuteleukemia in adults of European ancestry1 comprisingdistinct sub-groups characterized by unique somatic
genetic alterations, etiologies, and outcomes2. Rare germline
variants in transcription factors and other genes regulating
hematopoietic cell differentiation and proliferation are highly
penetrant for AML3, with some causative for debilitating human
syndromes that include AML as a component, while others cause
familial AML with high penetrance. Although such variants
demonstrate a role for genetics in AML susceptibility, they are
rare and do not make a major contribution to population disease
burden4. A modest increased risk of myeloid malignancy for first-
degree relatives of non-familial AML patients further supports a
role for genetics in disease susceptibility5, which for the majority
of cases is likely determined by co-inheritance of common low
penetrance variants consistent with the multigenic model for
complex human diseases6,7.
Outside of highly penetrant syndromic or familial disease, genetic
susceptibility to AML remains largely unexplained. To identify AML
risk loci we conducted three genome-wide association studies with
participants of European ancestry, with replication in a fourth study.
Here we report the identification of risk loci for AML, including pan-
AML irrespective of disease sub-type and for cytogenetically normal
AML. These data inform on disease etiology and demonstrate the
existence of common, low-penetrance susceptibility alleles for AML
with heterogeneity in risk across sub-types.
Results
Discovery meta-analysis of AML genome-wide association
studies (GWAS). We conducted three independent genome-wide
association studies with AML cases and controls of European
ancestry (GWAS 1-3). Following implementation of rigorous
quality metrics to each GWAS (Methods, Supplementary Fig. 1),
genotype data were available on 3041 AML cases and 6760
controls of European ancestry (Supplementary Figs. 2–5, Sup-
plementary Table 1). To improve genomic resolution, imputation
using the Haplotype Reference Consortium panel (http://
www.haplotype-reference-consortium.org/)8 was used to derive
estimated genotypes for >7 million single nucleotide poly-
morphisms (SNPs) for each study. We combined the association
test statistic for 6694056 autosomal SNPs common to all three
GWAS after exclusion of those with an INFO (imputation
quality) score of <0.6 and a minor allele frequency (MAF) of
<0.01, and conducted a meta-analysis under a fixed-effect model
for variants associating with AML. Given the genetic and biolo-
gical heterogeneity of AML, sub-type specific odds ratios (ORs)
were also calculated for the largest AML sub-group, cytogeneti-
cally normal AML (N= 822), using data for 6532175 SNPs
common to all three studies. Quantile-quantile plots of observed
versus expected P values (minor allele frequency (MAF) >0.01)
for all AML cases and cytogenetically normal AML cases showed
minimal inflation of test statistics across all three GWAS after
adjustment for nominally significant principal components in
each GWAS (λGC= 1.021, 1.025, and 1.055 for all AML in
GWAS1, GWAS2, and GWAS3, respectively; λGC= 1.006, 1.011,
and 1.025 for cytogenetically normal in GWAS1, GWAS2, and
GWAS3, respectively) (Supplementary Figs. 6–7), minimizing the
possibility of hidden population stratification and cryptic relat-
edness. Pooling data from three GWAS identified associations for
cytogenetically normal AML at 6p21.32 (rs3997854, HLA-DQA2)
and 4q22.3 (rs75391980) that surpassed genome-wide sig-
nificance (P ≤ 5 × 10−8), and additional suggestive associations
(P < 10−6) at 2q36.1 (rs4674579), 3q (rs2621279), 5q35.1
(rs13183143), 11q13.2 (rs11481), and 20p12.3 (rs6077414) for all
AML and at 9p21.1 (rs10969985) and 13q21.31 (rs143280565) for
cytogenetically normal AML (Supplementary Fig. 8, Supple-
mentary Table 2).
Validation GWAS and meta-analysis. To replicate the associa-
tions at the loci identified in the discovery GWAS meta-analysis we
conducted a fourth genome-wide association study of European
cases and controls (GWAS 4). Following the application of SNP and
sample quality control metrics (Supplementary Figs. 9 and 10), data
on >7.6 million SNPs from 977 AML cases and 3728 controls of
European ancestry were available for analysis, which included 465
cytogenetically normal AML cases (Supplementary Table 1).
Quantile–quantile plots of observed versus expected P values
(MAF > 0.01) showed minimal inflation of test statistics (λGC=
1.012 for all AML cases and λGC= 1.001 for cytogenetically normal
AML) (Supplementary Fig. 11). Analysis of data from GWAS 4
validated (P < 0.05) two of the associations identified in the dis-
covery GWAS meta-analysis, with consistent direction and mag-
nitude of effect sizes across all four studies, including 11q13.2
(rs4930561, KMT5B; P= 2.15 × 10−8) for all AML irrespective of
sub-type (N= 4018) and 6p21.32 (rs3916765, HLA-DQA2;
P= 1.51 × 10−10) for cytogenetically normal AML (N= 1287).
Meta-analysis of SNPs common to all four GWAS (N= 6661818
and N= 6496414 for all AML and cytogenetically normal AML,
respectively) also revealed additional borderline significant sus-
ceptibility loci at 1p31.1 (rs10789158, CACHD1, P= 2.25 × 10−7)
for all AML and at 7q33 (rs17773014, AKR1B1, P= 4.09 × 10−7)
for cytogenetically normal AML, both with consistent direction and
magnitude of effect across all four studies (Figs. 1 and 2). In order to
test for any potential effects of residual population substructure we
re-examined the top signals using only cases and controls of UK
origin in GWAS1, GWAS2, and GWAS4, and using only cases and
controls of German origin in GWAS3 (Supplementary Fig. 12). The
direction and magnitude of the associations in these sub-group
analyses (Supplementary Fig. 13) are very similar to the analyses
including all cases and controls (Fig. 2). As such, we report genome-
wide significant susceptibility loci for all AML and cytogenetically
normal AML at 11q13.2 (rs4930561) and 6p21.32 (rs3916765),
respectively, and borderline significant susceptibility loci for all
AML and cytogenetically normal AML at 1p31.1 (rs10789158) and
7q33 (rs17773014).
AML risk variants at 11q13.2, 6p21.32, 1p31, and 7q33 have
Bayesian false-discovery probabilities (BFDP)9 of 7, <1, 3, and
5%, respectively. There was no evidence of significant hetero-
geneity (P < 0.05) for association with AML for any of the risk
variants across the 4 GWAS studies (Fig. 2). Analysis condition-
ing on the top variant at each susceptibility locus did not identify
any evidence of additional associations (P < 10−4) within 500 kb
of the lead variant (Supplementary Figs. 14–17).
There was no significant heterogeneity in AML risk for any of
the four variants when cases and controls were stratified by age
(<55 years; ≥55 years) (Supplementary Table 3). Likewise, there
was no significant heterogeneity in AML risk for rs4930561
(11q13.2), rs10789158 (1p31.3), or rs17773014 (7q33) when cases
and controls were stratified by sex, although there was significant
heterogeneity for rs3916765 (6p21.32) with greater penetrance for
cytogenetically normal AML in females (OR 2.11, 95% CI
1.63–2.73) compared to males (OR 1.45, 95% CI 1.16–1.80;
I2= 78.47, PQ= 0.03) (Supplementary Table 4).
The relationship between AML risk variants and survival was
evaluated in 767 AML patients (excluding acute promyelocytic
leukemia) from the UK, Germany, and Hungary. However, none of
the 4 AML susceptibility variants identified here were significantly
associated with either relapse-free or overall survival in univariate
analysis that included all AML patients (N= 767) or those with
cytogenetically normal AML (N= 369) (Supplementary Figs. 18–21).
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A previously reported susceptibility variant for AML in the
BICRA gene (rs75797233)10 was not significantly associated with
AML risk in our study (GWAS meta-analysis odds ratio (OR)
1.06, 95% CI 0.87–1.29). However, this variant was imputed to
sufficient quality (INFO > 0.6) in only three GWAS studies and
statistical power to detect an association with AML for this
relatively uncommon variant (MAF 0.02) is compromised.
Inference of risk loci and biological function. We identified a
genome-wide significant association for rs4930561 with risk of AML
irrespective of sub-type (OR 1.17, 95% CI 1.11–1.24; P= 2.15 × 10−8)
which maps to the KMT5B gene on 11q13.2 (Fig. 3a). To identify
putative risk loci we interrogated data from a meta-analysis of 31624
blood samples collated by the eQTLGen consortium11 for evidence of
cis-regulated genes. Forty seven genes annotated to within 500Kb of
the association signal and the sentinel variant is a significant eQTL for
12 of these, including MRPL21 (Benjamini–Hochberg corrected P-
value [PBH]= 7.5 × 10−29), RP5-901A4.1 (PBH= 4.1 × 10−24),
ALDH3B1 (PBH= 4.48 × 10−18), IGHMBP2 (PBH= 2.85 × 10−16),
RP11-802E16.3 (PBH= 6.76 × 10−15), and CHKA (PBH= 1.73 ×
10−14), DOC2GP (PBH= 1.32 × 10−12), TCIRG1 (PBH= 7.83 ×
10−5), NDUFS8 (PBH= 1.69 × 10−4), UNC93B1 (PBH= 1.09 × 10−3),
PP1CA (PBH= 0.01), and RP11-554A11.9 (PBH= 0.01). rs4930561 is
Fig. 1 Manhattan plots from acute myeloid leukemia meta-analysis of 4 genome-wide association studies. For each GWAS, association tests were
performed for all AML cases and cytogenetically normal AML assuming an additive genetic model, with nominally significant principal components
included in the analysis as covariates. Association summary statistics were combined for variants common to all four GWAS, in fixed effects models using
PLINK. Manhattan plots show negative log10 (fixed effects meta P values, Y axis) for all AML (a) and cytogenetically normal AML (b) over 22 autosomal
chromosomes. Risk loci are annotated with chromosome position and local gene. All statistical tests were two-sided and no adjustments were made for
multiple comparisons. The horizontal red line denotes the threshold for statistical significance in a genome-wide association study (P < 5.0 × 10−8).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26551-x ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6233 | https://doi.org/10.1038/s41467-021-26551-x | www.nature.com/naturecommunications 3
not, however, an eQTL for KMT5B (PBH= 0.99) (Supplementary
Table 5).
We identified strong statistical evidence for an association
with cytogenetically normal AML for rs3916765 (OR 1.72, 95%
CI 1.46–2.03; P= 1.51 × 10−10), which maps to the HLA locus
on 6p21.32, intergenic to HLA-DQB1 and HLA-DQA2 within the
major histocompatibility (MHC) class II region (Fig. 3b). To
further explore the association between the HLA locus and risk
of cytogenetically normal AML we imputed classical HLA alleles
using 5225 Europeans from the Type I Diabetes Genetics
Consortium12 as a reference panel (Methods). HLA-DQB1*03:02
(r2= 0.56 with rs3916765) was significantly under-represented
in AML cases compared to controls in meta-analysis (OR 0.63,
95% CI 0.51–0.72, P= 8.9 × 10−8), identifying this as the most
likely classical HLA allele underpinning the association with
AML at the 6p21.32 locus (Supplementary Fig. 22). Likewise,
HLA-DQA1*03:01 (r2= 0.53 with rs3916765) was also signifi-
cantly under-represented in cases compared to controls (OR
0.77, 95% CI 0.68–0.87, P= 4.91 × 10−5) (Supplementary
Fig. 22). However, analysis conditioning on HLA-DQB1*03:02
rendered the association for the HLA-DQA1*03:01 allele
non-significant (OR 0.98, 95% CI 0.82–1.16, P= 0.79), consistent
with linkage disequilibrium between these two alleles
(r 2= 0.50).
Given the identification of a major AML risk allele at the HLA
locus on chromosome 6p21.32 and that cancer cells acquire
somatic mutations that can function as neo-antigens for immune
recognition we performed a case–control analysis stratified by
mutation status for NPM1 and FLT3, two genes commonly
mutated and clinically significant in cytogenetically normal
AML2. Specifically, data on NPM1 and FLT3 somatic mutation
status were available for 653 and 865 AML cases, respectively.
There was no significant heterogeneity in AML risk when cases
and controls were stratified by either NPM1 or FLT3 mutation
status, although there was a trend towards higher risk for NPM1-
mutated AML (OR 1.96, 95% CI 1.29–2.98; P= 1.7 × 10−3) and
FLT3-mutated AML (OR 1.52, 95% CI 1.07–2.16; P= 0.02)
compared to NPM1-wildtype AML (OR 1.28, 95% CI 0.97 –1.68;
P= 0.08) or FLT3-wildtpe AML (OR 1.26, 95% CI 1.01–1.58;
P= 0.04) (Supplementary Table 6).
We also identified a borderline significant association for
rs10789158 with AML irrespective of sub-type (OR 1.22, 95% CI
1.13–1.31; P= 2.25 × 10−7) which maps to a block of linkage
disequilibrium upstream of the CACHD1 gene on chromosome
1p31.3 (Fig. 3c). Of the 11 genes annotated to within 500 Kb of
the association signal, the sentinel SNP (rs10789158) is eQTL for
RAVER2 (PBH= 1.26 × 10−2) and AK4 (PBH= 1.26 × 10−2)
where the AML risk variant is associated with higher expression
of AK4 and lower expression of RAVER2 (Supplementary
Table 7).
We also identified a borderline statistically significant associa-
tion with cytogenetically normal AML for rs17773014 (OR 1.26,
95% CI 1.15–1.37; P= 4.09 × 10−7), which maps close to the
AKR1B1 gene on chromosome 7q33 (Fig. 3d). Nine genes were
annotated to within 500 Kb of the association signal and
the sentinel SNP (rs17773014) is a significant eQTL for AKR1B1
in whole blood with the AML risk allele associated with higher
transcript levels (PBH= 5.32 × 10−23) (Supplementary Table 8).
We cannot exclude an association with related superfamily
member AKR1B10, which maps close to AKR1B1 on
a
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Fig. 2 Forest plots for 4 new loci associated with acute myeloid leukemia. Study cohorts, sample sizes (case and controls (con)), imputation (info) score,
effect allele, effect allele frequencies (EAF), and estimated odds ratios (OR) for rs4930561 (a), rs3916765 (b), rs10789158 (c), and rs17773014 (d). The
vertical line corresponds to the null hypothesis (OR= 1). The horizontal lines and square brackets indicate 95% confidence intervals (95% CI). Areas of the
boxes are proportional to the weight of the study. Diamonds represent combined estimates for fixed‐effect and random‐effect analysis. Cochran’s Q
statistic was used to test for heterogeneity such that PHET > 0.05 indicates the presence of non-significant heterogeneity. The heterogeneity index, I2
(0–100) was also measured which quantifies the proportion of the total variation due to heterogeneity. All statistical tests were two-sided and no
adjustments were made for multiple comparisons.
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chromosome 7q33 but which was not annotated in the eQTLGen
consortium dataset.
Discussion
By conducting a meta-analysis of three large genome-wide studies
with validation in a fourth study, we identify four susceptibility
loci for AML, demonstrating the existence of common, low-
penetrance susceptibility alleles for this genetically complex dis-
ease. Specifically, our data identify a major susceptibility locus for
AML at the 11q13.2 KMT5B gene. KMT5B (SUV420H1) encodes a
lysine methyltransferase that is frequently mutated in human
cancers, with gene amplifications being particularly common13–15.
Fig. 3 Regional association and linkage disequilibrium plots for 4 new loci associated with acute myeloid leukemia. For each GWAS, association tests
were performed for all AML cases and cytogenetically normal AML assuming an additive genetic model, with nominally significant principal components
included in the analysis as covariates. Association summary statistics were combined for variants common to all four GWAS, in fixed effects models using
PLINK. Negative log10-transformed P values (left Y axis) from the meta-analysis of four GWAS are shown for SNPs at 11q13 (a) and 1p31.1 (c) for all AML
irrespective of sub-type, and at 6p21.32 (b) and 7q33 (d) for cytogenetically normal AML. All statistical tests were two-sided and no adjustments were
made for multiple comparisons. The lead SNP at each location is indicated by a purple diamond and the blue line shows recombination rate (right Y axis).
All plotted SNPs were either directly genotyped or had an imputation score of >0.6 in all four GWAS datasets. Included are functional annotation tracks
from ENCODE showing regulatory activity in H1 human embryonic stem cells (H1hesc) and K562 myeloid leukemia cells. TSS transcription start site, PF
promoter flank, E enhancer, WE weak enhancer, CTCF CCCTC-binding factor site, T transcribed.
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KMT5B is implicated in AML pathogenesis where mutation has
been associated with transformation from precursor myelodys-
plastic syndrome to AML16. Mutations in other lysine methyl-
transferases such as KMT2A (MLL1) occur with high frequency in
AML17. Although KMT5B is a strong candidate for an AML
susceptibility gene a priori we cannot exclude mechanisms
involving other local genes. For example, the AML risk variant at
the 11q13.2 susceptibility locus is significantly associated with
lower expression of CHKA, which encodes a protein involved in
phosphatidylcholine biosynthesis. CHKA is significantly upregu-
lated in mouse haematopoietic stem cells and human leukemia cell
lines upon restoration of TET2 function18, a tumor suppressor
which blocks aberrant self-renewal and which is frequently
mutated in AML resulting in loss of function19.
We also report a putative pan-AML susceptibility locus at
1p31.3 that is cis-eQTL for RAVER2 and AK4. RAVER2 encodes a
ribonucleoprotein involved in RNA splicing where expression
associates with transformation from myelodysplastic syndrome to
AML20. In both human and mouse hematopoietic stem cells
RAVER2 is identified as a target gene for miR-9921, which reg-
ulates normal and malignant hematopoietic stem cell self-
renewal21,22 and expression is significantly associated with
prognosis in AML22. AK4 belongs to the adenylate kinase (AK)
family of proteins that catalyze the phosphorylation of nucleotide
monophosphate precursors to their di- and triphosphate forms.
AK4 is localized to the mitochondria and is a target gene for
hypoxia-inducible factor 1 alpha (HIF-1α)23, an established
tumor suppressor in human and murine AML24,25.
We also identify a major susceptibility locus for cytogenetically
normal AML at the 6q21.32 HLA gene. This region carries suscept-
ibility alleles for numerous human cancers including hematological
malignancies such as chronic lymphocytic leukemia26,27 and Hodgkin
lymphoma28, where risk is mediated via differential antigenic pre-
sentation/T-cell receptor recognition or altered risk of oncogenic
infection. Somatic dysregulation of antigenic presentation through
altered gene expression, loss of heterozygosity or genomic deletion is a
common feature of many human solid cancers leading to failed
immune surveillance29–31. Somatic loss of HLA alleles is rare in AML
at disease presentation although it has been reported as a mechanism
of immune escape after bone marrow transplant leading to
relapse32–35. Our data identify the HLA-DQB1*03:02 and HLA-
DQA1*03:01 alleles as significantly under-represented in cytogeneti-
cally normal AML cases compared to controls. Cytogenetically nor-
mal AML is characterized by somatic mutation in genes such as
NPM1 and FLT32 which can function as neo-antigens36–40. For
example, NPM1 mutation is reported in up to 60% of cytogenetically
normal AML41,42 where mutation leads to aberrant cytoplasmic
expression that is postulated to lead to more efficient HLA
presentation43. Our data suggest that rs3916765 affects AML risk by
modulating immune recognition of mutated cells, although further
work is required to determine which leukemia-specific neo-antigens
are involved. The DQB1*03:02-DQA1*03:01 haplotype is associated
with increased risk of autoimmune diseases including celiac disease44
and type 1 diabetes45,46. Reports of concomitant celiac disease and
AML are very rare47 consistent with the DQB1*03:02-DQA1*03:01
haplotype having pleiotropic and opposing effects on risk of these two
diseases. Taken together, these data implicate dysregulated immune
function as a risk modifier for cytogenetically normal AML.
Our data suggest that differential expression of cis-regulated
AKR1B1 (or related superfamily member AKR1B10) at the 7q33
locus modulates risk of cytogenetically normal AML. AKR1B1
and AKR1B10 encode members of the aldo-ketoreductase
superfamily which catalyze the reduction of numerous alde-
hydes, including the aldehyde form of glucose to generate fructose
via the polyol pathway48. Altered glucose metabolism is a hall-
mark of cancer, where malignant cells switch energy production
from mitochondrial oxidative phosphorylation to glycolysis49. In
AML, a switch to glycolytic metabolism is associated with disease
progression and poor outcome50. Unlike normal monocytes,
AML cells can also utilize fructose as an alternative substrate for
glycolysis with expression of the GLUT5 fructose transporter as a
major regulator of fructose metabolism in leukemic blast
cells51,52, and where high expression is associated with increased
proliferation, clonogenicity, migration, and invasion of AML
cells51. Interrogation of three independent datasets identified a
consistent association between elevated AKR1B1 transcript levels
and shorter overall survival in AML53 and serum fructose levels
are prognostic in AML51, further implicating this pathway in
AML disease progression.
In summary, our study identifies common susceptibility alleles
at four genomic locations that modify AML risk, with evidence of
sub-type specific risk loci reflecting the existence of multiple
etiological pathways to disease development. Further work is
required to decipher the functional basis of these risk loci
although our data builds on existing evidence demonstrating a
role for aberrant histone modification and altered fructose
metabolism in AML pathogenesis16,17,51,52. Furthermore, the
identification of a major AML risk variant at the HLA locus on
chromosome 6 implicates altered immune function as etiologi-
cally important in AML. Our data supports existing evidence of
genetic and biological heterogeneity in AML2 and confirm the
need for large collaborative studies to improve statistical power
and aid the discovery of sub-type specific genetic risk loci.
Methods
Study participants. GWAS1 comprised 1119 AML cases of European ancestry
from UK Medical Research Council/National Cancer Research Institute AML
clinical trials (N= 529)54,55, the Eurobank transplant study (N= 70)56, the Leu-
kaemia and Lymphoma Research adult acute Leukaemia population-based case
control epidemiology study (N= 222)57,58, and the institutional hematology bio-
banks of Newcastle University (N= 48) and University of Chicago (N= 250).
Cases were genotyped on the Illumina Omni Express/Omni Express Exome
BeadChips. For controls, we used publicly available Illumina Hap550K BeadChip
data on 2671 individuals from the British 1958 Birth Cohort59.
GWAS2 comprised 931 AML cases of European ancestry from the Central
England Haemato-Oncology and Oncology Research Bank (N= 120) and King’s
College London Medical School (N= 144) with cases recruited from local
treatment centers and UK clinical trials. AML cases were also obtained from the
Study Alliance Leukemia biobank at Dresden University (N= 208)60,61, the
CALGB 9710 APL clinical trial (N= 101)62, the Newcastle University Haematology
Biobank (N= 248), and the Munich Leukemia Laboratory (N= 53) which provides
a nationwide diagnostic service in Germany. AML cases were also obtained from
treatment centers at the Medical University of Graz (N= 32), University Hospital
Rigshospitalet Copenhagen (N= 13), and the Universita Cattolica Sacro Cuore
Rome (N= 12). All cases were genotyped on the Illumina Omni Express Exome
BeadChip. For controls, we used publicly available Illumina Hap1.2M-Duo data on
2477 individuals from the UK Blood Service Control Group, part of the Wellcome
Trust Case Control Consortium 2 controls63.
GWAS3 comprised 991 AML cases of European ancestry from treatment
centers at the Department of Hematology and Oncology of the Medical Faculty
Mannheim, University of Heidelberg, Germany (N= 82)64, the Centre Hospitalier
Universitaire Nice, France (N= 42)65, and the University of London UK
(GSE20672) (N= 40). AML cases were also obtained from the Austrian Academy
of Sciences (N= 223)66, the Acute Leukaemia French Association Clinical Trials at
the University of Lille, France (N= 278)67,68, the Biobank La Fe at the Hospital
Universitari i Politècnic La Fe, Spain (N= 15)69, the German-Austria AML Study
Group the German-Austrian AML Study Group (GSE32462, N= 18970;
GSE34542, N= 3371; GSE46745, N= 33; GSE46951, N= 5172), and the
Cooperative Health Research in the region of Augsburg (KORA) study (N= 5)73.
For controls, we used data from 1612 individuals recruited to KORA study73. All
genotyping data for cases and controls were generated on the Affymetrix
SNP6.0 Array.
GWAS4 (replication) comprised 977 AML cases of European ancestry from the
Central England Haemato-Oncology and Oncology Research Bank (N= 515),
treatment centers at the Hematology Division at Semmelweis University, Budapest
(N= 202)74 and the UK Biobank (N= 260), a large population-based study
conducted in the United Kingdom. For controls, we used 3728 individuals from the
UK Biobank. Cases and controls were genotyped on the Affymetrix UK BiLEVE
Axiom array or the Affymetrix UK Biobank Axiom array with an equal proportion
of cases and controls genotyped on each array.
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Collection of patient samples and associated clinico-pathological information
was undertaken with written informed consent. All studies were conducted in
accordance with the Declaration of Helsinki and received local institutional review
board or national research ethics approval (Supplementary Table 9). Specifically,
this research has been conducted using the UK Biobank Resource (Application
#16583, James Allan). MRC/NCRI AML 11 trial, AML 12 trial and the UK
Leukaemia Research Fund (LLR) population-based case–control study of adult
acute leukemia received multicenter research ethics committee approval54,55,75.
Research ethics committee approval was given to the Newcastle Haematology
Biobank (07/H0906/109+ 5) and the AML genome-wide association study in the
UK (06/q1108/92, BH136664 (7078)). AML cases and controls for Samples from
the Hungarian AML patients were obtained during the standard diagnostic workup
at the Hematology Divisions of the 1st and 3rd Department of Internal Medicine,
Semmelweis University, Budapest, following ethical approval from the Local
Ethical Committee (REF TUKEB-1552012) and the Hungarian Medical Research
Council (REF 45371-2/2016/EKU). Saliva and fibroblast samples from Austrian
AML patients were collected at the Division of Hematology, Medical University of
Graz, Graz, Austria76. The diagnosis of AML was made in accordance with World
Health Organisation guidelines.
Genotyping and genome-wide quality-control procedures. Genotype calling was
performed using Illumina GenomeStudio software or Affymetrix Genotyping
Console software v4.2.0.26. Data handling and analysis was performed using R
v3.5.1, PLINK v1.9b4.4, and SNPTEST v2.5.2. Rigorous SNP and sample quality
control metrics were applied to all four GWAS (Supplementary Fig. 1). Specifically,
we excluded SNPs with extreme departure from Hardy–Weinberg equilibrium
(HWE; P < 10−3 in either cases or controls) and with a low call rate (<95%). We
also excluded SNPs that showed significant differences (P < 10−3) between geno-
type batches and with significant differences (P < 0.05) in missingness between
cases and controls. Individual samples with a call rate of <95% or with extreme
heterozygosity rates (±3 standard deviation from the mean) were also excluded
from each GWAS. Individuals were removed such that there were no two indivi-
duals with estimated relatedness pihat >0.1875, both within and across GWAS. The
individual with the higher call rate was retained unless relatedness was identified
between a case and a control, where the case was preferentially retained. Ancestry
was assessed using principal component analysis and super-populations from the
1000 genomes project as a reference, with individuals of non-European ancestry
excluded based on the first two principal components. In order to minimize any
impact of population stratification among the European population we excluded
outlying cases and controls identified using principal components 1 and 2 for each
GWAS (Supplementary Figs. 1, 3, 4, 5, and 10).
Imputation, genome-wide association testing, and meta-analysis. Genome-
wide imputation for each GWAS was performed using the Michigan Imputation
Server (https://imputationserver.sph.umich.edu/index.html#!) and the Haplotype
Reference Consortium reference haplotype panel (http://www.haplotype-reference-
consortium.org/) following pre-phasing using ShapeIT (v2.r790)77. All variants
with an imputation info score <0.6 or a minor allele frequency of <0.01 were
excluded from subsequent analysis.
For each GWAS, association tests were performed for all cases and
cytogenetically normal AML assuming an additive genetic model, with nominally
significant principal components included in the analysis as covariates. Association
summary statistics were combined for variants common to GWAS 1, GWAS 2, and
GWAS 3, and then for variants common to all four GWAS, in fixed effects models
using PLINK v1.9b4.4. Cochran’s Q statistic was used to test for heterogeneity and
the I2 statistic was used to quantify variation due to heterogeneity.
The Bayesian false discovery probability was calculated using a prior probability
of association of 0.0001 and a plausible OR of 1.39.
Case–control analyses were also performed stratified by sex and age in all 4
GWAS. For age, cases and controls were stratified into those <55 years and ≥55
years. GWAS 1 was not included in the meta-analysis for the ≥55 age group
because the controls were recruited to the 1958 Birth Cohort and were all
genotyped at the age of 45 years. Case–control analyses were performed stratified
by NPM1 and FLT3 mutation status (mutation-positive and mutation-negative) in
GWAS 2 and GWAS 4. Data on NPM1 and FLT3 somatic mutation status was
available for 653 and 865 AML cases, respectively, including 411 and 528 cases of
cytogenetically normal AML, respectively. PCR mutation analysis was performed
as part of routine diagnostics for NPM1 exon 12 and FLT3 exons 14–15
(Supplementary Table 10)78,79.
Technical validation of AML susceptibility variants. All four AML risk variants
reported here were either directly genotyped or imputed to high quality. Specifi-
cally, rs4930561 was directly genotyped in GWAS 1 and GWAS 2 and imputed in
GWAS 3 and GWAS 4 (info score 0.974–0.988); rs3916765 was genotyped in
GWAS 4 and imputed in GWAS 1, GWAS 2, and GWAS 3 (info score
0.901–0.995); rs10789158 was imputed in all 4 GWAS studies (info score
0.946–0.9775); and rs17773014 was directly genotyped in GWAS 3 and GWAS 4
and imputed in GWAS 1 and GWAS 2 (info score 0.985–0.993). Fidelity of array
genotyping and imputed dosages was confirmed using Sanger sequencing in a
subset of AML samples (including samples genotyped on both Illumina and
Affymetrix platforms) for each sentinel variant with perfect or very high con-
cordance for all four variants (Supplementary Figs. 23–26).
The majority of AML cases were genotyped using DNA extracted from cell/
tissue samples (blood and bone marrow) taken during AML remission. A minority
of AML cases were genotyped using DNA extracted from tissue samples that
include leukemic AML cells. As such, we employed a stringent HWE cut-off
(Supplementary Fig. 1) in order to eliminate SNPs potentially affected by somatic
copy number alterations. Furthermore, we also used Nexus Copy Number v10
(BioDiscovery, California) to interrogate B allele frequency and Log R ratio values
at loci associated with AML following genotyping of DNA extracted from leukemic
AML cells. For rs4930561 (chromosome 11q13.2) we interrogated data from 352
AML cases using samples with high somatic cell content and found one case with a
large deletion capturing the KMT5B locus. We also identified 12 cases with
evidence of trisomy 11 or large gains affecting chromosome 11, consistent with
reports of trisomy 11 in approximately 1% of AML cases80. For rs10789158
(chromosome 1p31.3) we identified 1 case with evidence of copy number gain. The
susceptibility locus at chromosome 1 does not fall within a region reported to be
recurrently somatically deleted or amplified in AML. The association signals at
6p21.32 (rs3916765) and 7q33 (rs17773014) were specific to cytogenetically normal
AML and evidence of somatic copy number alterations were visible in 0 and 3
cases, respectively (based on Nexus Copy Number analysis of 127 cytogenetically
normal AML cases). Specifically, there were three cases with evidence of deletions
affecting the chromosome 7 risk locus that were not visible cytogenetically.
Furthermore, there was no evidence of copy neutral loss of heterozygosity (>2Mb)
at any of the four AML susceptibility loci reported here. Taken together, these data
limit the possibility of differential genotyping in cases and controls due to
somatically acquired allelic imbalance.
HLA imputation, expression quantitative trait loci (eQTL) analysis, and
functional annotation. Imputation of classical HLA alleles was performed using
the SNP2HLA v1.0.3 tool using 5225 Europeans from the Type I Diabetes Genetics
Consortium as a reference panel12. To examine the relationship between SNP
genotype and gene expression and identify cis expression quantitative trait loci
(eQTLs) we made use of data from the eQTLGen Consortium (http://
www.eqtlgen.org/cis-eqtls.html) for whole blood. Benjamini–Hochberg (BH)-
adjusted P values were estimated for each gene annotated to within 1 Mb of the
sentinel SNP at each AML association signal. Regions with AML susceptibility
variants were annotated for putative functional motifs using data from the
ENCODE project81.
Relationship between SNP genotype and patient survival. The relationship
between AML risk variants and survival was evaluated in a total of 767 AML
patients (excluding acute promyelocytic leukemia) from the UK54,55, Germany60,61,
and Hungary74. Briefly, patients were treated with conventional intensive AML
therapy including ara-C, daunorubicin, and best supportive care. A subset of high-
risk patients in the German cohort were treated with stem cell transplantation60.
Overall survival was defined as the time from diagnosis to the date of last follow-up
or death from any cause. Data on relapse-free survival was available on 358 AML
patients, which was defined as the time from date of first remission to the date of
last follow-up in remission or date of AML relapse. Cox regression analysis was
used to estimate allele-specific hazard ratios and 95% confidence intervals for each
study in analyses that included all AML cases (N= 767) and cytogenetically normal
AML (N= 358).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Genome-wide association summary statistics (Lin_AML_metaassoc.txt) are available for
download from https://doi.org/10.25405/data.ncl.16558116.v1. AML case and control
genotyping data from the UK Biobank can be obtained via application through https://
www.ukbiobank.ac.uk/. Genotyping data on 2699 individuals recruited to the 1958 British
Birth Cohort (Hap1.2M-Duo Custom array data) and 2501 individuals from the UK Blood
Service are available from the Wellcome Trust Case Control Consortium 2 [https://www.
wtccc.org.uk/;WTCCC2:EGAD00000000022,%20EGAD00000000024]. Case and control
genotyping data from 1615 individuals recruited to the KORA study can be obtained via
application at https://www.helmholtz-muenchen.de/en/kora/. Other genotyping data
supporting the findings of this study can be found as deposited in NCBI Gene Expression
Omnibus under accession numbers GSE20672, GSE32462, GSE34542, GSE46745, and
GSE46951. eQTL data is available from the eQTLGen consortium via http://www.eqtlgen.org/
cis-eqtls.html. ENCODE data is available from https://www.encodeproject.org/biosamples/
ENCBS718AAA/ for H1 human embryonic stem cells (H1hesc) and from https://www.
encodeproject.org/biosamples/ENCBS109ENC/ for K562 myeloid leukemia cells. URLs:
Michigan Imputation Server, https://imputationserver.sph.umich.edu/index.html#!; Haplotype
Reference Consortium, http://www.haplotype-reference-consortium.org/; eQTLGen
Consortium, http://www.eqtlgen.org/cis-eqtls.html; 1000 Genomes Project, https://www.
internationalgenome.org/; PLINK, https://www.cog-genomics.org/plink2/; SNPTEST2,
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medschl.cam.ac.uk/;76 UK Biobank, https://www.ukbiobank.ac.uk/; Central England
Haemato-Oncology and Oncology Research Bank, https://bwc.nhs.uk/central-england-
haemato-oncology-and-oncology-research-bioba/; Newcastle University Biobank, https://
www.ncl.ac.uk/biobanks/; WTCCC, https://www.wtccc.org.uk/; ENCODE, https://
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